DABP Inhibitors
DABP inhibitors are chemicals that inhibit the function of the DABP enzyme, a critical component in various biochemical pathways within cells. The chemical structure of DABP inhibitors typically consists of a central core scaffold adorned with functional groups that facilitate binding to the active site of the DABP enzyme. This interaction disrupts the enzyme's normal catalytic function, leading to intricate cellular responses that are currently being explored in scientific research.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Inhibits EGFR tyrosine kinase activity, blocking downstream signaling pathways that promote cell proliferation and survival. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Targets BCR-ABL tyrosine kinase, blocking signals that drive leukemia growth and inhibiting c-KIT and PDGFR kinases in gastrointestinal stromal tumors. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Inhibits multiple kinases, including Raf, VEGFR, and PDGFR, hindering tumor angiogenesis and cell proliferation. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Targets VEGFR, PDGFR, and other kinases, impeding angiogenesis and tumor cell growth. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Blocks EGFR tyrosine kinase, inhibiting downstream signaling involved in cancer cell growth and survival. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Inhibits both EGFR and HER2 tyrosine kinases, interfering with signaling pathways that promote cancer cell proliferation. | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $117.00 $423.00 | 11 | |
Specifically inhibits mutated BRAF kinase in melanomas with the V600E mutation, reducing cell proliferation and survival. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Blocks CDK4/6 kinases, leading to G1 cell cycle arrest and inhibiting cell division in estrogen receptor-positive breast cancers. | ||||||
Ribociclib | 1211441-98-3 | sc-507367 | 10 mg | $450.00 | ||
Similar to Palbociclib, inhibiting CDK4/6 to halt cell cycle progression in hormone receptor-positive breast cancers. | ||||||
Abemaciclib | 1231929-97-7 | sc-507342 | 10 mg | $110.00 | ||
Another CDK4/6 inhibitor, limiting cell cycle progression and proliferation in hormone receptor-positive breast cancers. | ||||||